UNC Lineberger Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, UNC Lineberger Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count).
UNC Lineberger Comprehensive Cancer Center: 366 sponsored US clinical trials, 79 recruiting.
UNC Lineberger Comprehensive Cancer Center sponsors 366 registered US clinical trials on ClinicalTrials.gov, 79 of them currently recruiting, and 209 completed. 2 of these trials are in Phase 3-4 (later-stage) and 157 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 29 trials.
Top-decile sponsor footprint
UNC Lineberger Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
209 of 246 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
366 total, page 7 of 8
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
NCT01298570
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT01234467
Retinal Oxygen Function After Radiation Therapy
NCT02043470
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
NCT00448201
North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)
NCT02564120
Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer
NCT01725048
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
NCT01262820
Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients
NCT01305954
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
NCT01169012
Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer
NCT01175967
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
NCT01344824
Trisenox® in Women With Metastatic Endometrial Cancer
NCT01184053
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
NCT01164215
Biomarkers in Blood Samples From Older Breast Cancer Survivors
NCT01138345
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
NCT01204450
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
NCT01011010
Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases
NCT01528878
Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy
NCT01132833
Digital Breast Tomosynthesis Preference Study
NCT00776126
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00744354
Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis
NCT00767468
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
NCT00764322
Radiation Induced Cardiopulmonary Injury in Humans
NCT02259452
Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment
NCT00610948
Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00577694
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors
NCT00573690
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
NCT00519831
Visibility of Lesion Characteristics With Phase Contrast Mammography
NCT00467727
Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids
NCT00489216
Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer
NCT00405366
Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
NCT00483405
Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT00320073
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors
NCT00307255
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
NCT00334438
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
NCT00380029
Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer
NCT00379509
Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer
NCT00454324
Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC
NCT00283244
Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia
NCT00499759
Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy
NCT00486304
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00280150
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00266110
Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
NCT00232505
Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00246753
Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
NCT00448357
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
NCT00227032
Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer
NCT00719173
Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer
NCT00225420
Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT00257426
Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer
NCT00499395
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 71 |
| Phase 2 | 86 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the UNC Lineberger Comprehensive Cancer Center pipeline
79 recruiting of 366 indexed (22% open); 209 completed (57%).
Phase mix: 2 late (III/IV) vs 157 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
UNC Lineberger Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 366 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
UNC Lineberger Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 366 trials (± recruiting share)
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Women and Infants Hospital of Rhode Island · 22% recruiting · 65 trials
- Merck Sharp & Dohme · 22% recruiting · 558 trials
- Henry M. Jackson Foundation for the Advancement of Military Medicine · 22% recruiting · 60 trials
- AbbVie · 21% recruiting · 526 trials
Related
What to do with this UNC Lineberger Comprehensive Cancer Center page
366 registered trials is a research-attention snapshot, not an endorsement of UNC Lineberger Comprehensive Cancer Center or any single study.
- 79 of UNC Lineberger Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition UNC Lineberger Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
UNC Lineberger Comprehensive Cancer Center pipeline card: 366 registered trials from official public datasets.Report a data error.